Clinical trials: active, in Switzerland
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
- Trial name
- NCT04586231
- Testing
- Belzutifan, Lenvatinib, Cabozantinib
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 747 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum…
- Trial name
- NCT05920356
- Testing
- Sotorasib, Pembrolizumab
- Where
- 418 sites in United States, Argentina and 36 more
- Volunteers
- 750 people
- Sponsor
- Amgen
Pulmonary Embolism
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
The objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE).
- Trial name
- NCT04798261
- Testing
- Indigo Aspiration System
- Where
- 79 sites in United States, Australia and 10 more
- Volunteers
- 1,500 people
- Sponsor
- Penumbra Inc.
Primary Hypercholesterolemia, Mixed Dyslipidemia
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical…
- Trial name
- VICTORION REAL (NCT05399992)
- Testing
- Inclisiran
- Where
- 40 sites in Austria, China and 6 more
- Volunteers
- 847 people
- Sponsor
- Novartis Pharmaceuticals
Apnea of Prematurity
nCPAP-NAVA-Backup Versus Standard nCPAP for Severe Apnea in Preterm Infants ≤28 Weeks
The goal of this clinical trial is to determine whether nasal continuous positive airway pressure (nCPAP) with neurally adjusted ventilatory assist (NAVA) backup ventilation (nCPAP-NAVA-backup mode) reduces the rate of severe…
- Trial name
- NAVAPNEA (NCT07923604)
- Testing
- nCPAP-NAVA-backup mode, nCPAP mode
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- University Hospital, Geneva
Glioblastoma
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to…
- Trial name
- EF-41 (NCT06556563)
- Testing
- Optune® device, Temozolomide, Pembrolizumab
- Where
- 102 sites in United States, Canada and 10 more
- Volunteers
- 741 people
- Sponsor
- NovoCure GmbH
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
- Trial name
- RASolve 301 (NCT06881784)
- Testing
- daraxonrasib, docetaxel
- Where
- 199 sites in United States, Australia and 17 more
- Volunteers
- 590 people
- Sponsor
- Revolution Medicines, Inc.
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF)
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF)…
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
- Trial name
- MANIFEST-3 (NCT07357727)
- Testing
- Pelabresib, Ruxolitinib
- Where
- 164 sites in United States, Argentina and 20 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
- Trial name
- DeLLphi-305 (NCT06211036)
- Testing
- Tarlatamab, Durvalumab
- Where
- 219 sites in United States, Argentina and 27 more
- Volunteers
- 563 people
- Sponsor
- Amgen
Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal
Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
Background: Perimesencephalic subarachnoid hemorrhage (pmSAH) is a distinct subtype of traumatic subarachnoid hemorrhage (SAH) characterized by a localized bleeding pattern around the midbrain not resulting from a ruptured…
- Conditions
- Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal, Perimesencephalic Subarachnoid Hemorrhage, Basilar Artery Perforator Aneurysm
- Trial name
- DECIPHER-pmSAH (NCT07923084)
- Testing
- Completion of a patient-reported outcome measure (PROM) in the form of a EQ-5D questionnaire
- Where
- Switzerland
- Volunteers
- 264 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced…
- Trial name
- NCT05384626
- Testing
- Neladalkib (NVL-655), Midazolam, Repaglinide
- Where
- 74 sites in United States, Australia and 13 more
- Volunteers
- 840 people
- Sponsor
- Nuvalent Inc.
SIBO, Endometriosis
Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Women With Endometriosis
This is a prospective, single-arm observational diagnostic study without therapeutic intervention or control arm. Participants undergo diagnostic assessment for SIBO including lactulose hydrogen/methane breath testing and…
- Trial name
- Endo-SIBO (NCT07922408)
- Testing
- Gastroduodenoscopy, luminal aspirate, mucosal biopsies, collection of mucus, lactulose breath test
- Where
- Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cancer
Pan Tumor Rollover Study
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
- Trial name
- NCT03899155
- Testing
- Nivolumab, Ipilimumab, Cabozantinib
- Where
- 410 sites in United States, Argentina and 36 more
- Volunteers
- 1,500 people
- Sponsor
- Bristol-Myers Squibb
Iron Absorption, Iron Deficiencies
Iron Absorption From a Nutritional Iron Supplement
Conventional oral iron supplements often cause gastrointestinal side effects and are limited by poor bioavailability, leaving unabsorbed iron to reach the colon.
- Trial name
- NCT07921433
- Testing
- Iron-Enriched Hydrogel Supplement (A with breakfast), Iron-Enriched Hydrogel Supplement (B with breakfast), Iron-Enriched Hydrogel Supplement (A without breakfast)
- Where
- Switzerland
- Volunteers
- 22 people
- Sponsor
- ETH Zurich
Intubation
AI-assisted Tracheal Intubation in Children
The aim of this study is to investigate whether the use of larynGuide™ provides accurate and reliable information regarding the position of the endotracheal tube following an intubation attempt in children.
- Trial name
- DOLPHIN (NCT07922434)
- Testing
- LarynGuide
- Where
- Switzerland
- Volunteers
- 110 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2)
Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
This single-centre, randomized, double-blind, placebo-controlled phase 2 trial investigates whether lowering cortisol with osilodrostat improves blood-glucose control in adults with mild autonomous cortisol secretion (MACS) and…
- Trial name
- GLYCOSIL-MACS (NCT07922148)
- Testing
- Osilodrostat (Isturisa), hydrocortisone 10mg
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Beckey Trinh
Neovascular Age-related Macular Degeneration
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
- Trial name
- Sightspire (NCT06847542)
- Testing
- Susvimo PDS Implant, Ranibizumab
- Where
- 64 sites in Austria, Czechia and 11 more
- Volunteers
- 250 people
- Sponsor
- Hoffmann-La Roche
NASH With Fibrosis, MASH With Fibrosis
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3).
- Trial name
- NCT06215716
- Testing
- Efruxifermin
- Where
- 361 sites in United States, Argentina and 16 more
- Volunteers
- 1,650 people
- Sponsor
- Akero Therapeutics, Inc
Non Small Cell Lung Cancer
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery.
- Trial name
- ADOPT-lung (NCT06284317)
- Testing
- Adjuvant durvalumab
- Where
- 44 sites in Australia, Austria and 8 more
- Volunteers
- 290 people
- Sponsor
- ETOP IBCSG Partners Foundation
Hypertension, Diabetes Mellitus, Type 2
Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition
The SOFIA study evaluates a web-based health application for people living with one or more chronic conditions. The study aims to find out whether the SOFIA application is useful, easy to use, and used over time by participants.
- Conditions
- Hypertension, Diabetes Mellitus, Type 2, Obesity
- Trial name
- SOFIA (NCT07916753)
- Testing
- SOFIA application
- Where
- Switzerland
- Volunteers
- 1,600 people
- Sponsor
- Fondation Net-Care.ch
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.